Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
Saved in:
| Title: | Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial. |
|---|---|
| Authors: | De Corso E; Otorhinolaryngology-Head and Neck Surgery, A Gemelli Hospital Foundation IRCCS, Rome, Italy. Electronic address: eugenio.decorso@policlinicogemelli.it., Canonica GW; Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Heffler E; Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Springer M; Specialized Non-Public Health Care Facility Alergologia Plus, Allergy Diagnostics and Therapy Center, Poznań, Poland., Grzegorzek T; Department of Otorhinolaryngology, Angelius Provita Medical Center, Katowice, Poland., Viana M; Othorhinolaryngology Department, Hospital Pedro Hispano, Matosinhos, Portugal., Horváth Z; Otorhinolaryngology Department, Szent Imre University Teaching Hospital, Budapest, Hungary., Mullol J; Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic Barcelona, FRCB-IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain., Gevaert P; Upper Airways Research Laboratory, Department of Head and Skin, Ghent University, Ghent, Belgium., Michel J; Aix Marseille University, APHM, CNRS, IUSTI, La Conception University Hospital, ENT-HNS Department, Marseille, France., Peters AT; Allergy-Immunology Division and the Sinus and Allergy Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Wagenmann M; Department of Otorhinolaryngology, Düsseldorf University Hospital (UKD), Düsseldorf, Germany., Zaghloul S; Sanofi, Morristown, NJ, USA., Zhang M; Sanofi, Morristown, NJ, USA., Corbett M; Sanofi, Morristown, NJ, USA., Nash S; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Angello JT; Sanofi, Morristown, NJ, USA., Radwan A; Regeneron Pharmaceuticals, Uxbridge, UK., Deniz Y; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Martin A; Sanofi, Cambridge, MA, USA., Hellings PW; University Hospitals Leuven, Leuven, Belgium. |
| Source: | The Lancet. Respiratory medicine [Lancet Respir Med] 2025 Dec; Vol. 13 (12), pp. 1067-1077. Date of Electronic Publication: 2025 Sep 28. |
| Publication Type: | Clinical Trial, Phase IV; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
